Leerink Partners Initiates Coverage On ShockWave Medical with Outperform Rating, Announces Price Target of $263
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Mike Kratky initiates coverage on ShockWave Medical (NASDAQ:SWAV) with an Outperform rating and announces a price target of $263.
October 16, 2023 | 3:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ShockWave Medical received an Outperform rating from Leerink Partners, with a price target of $263.
The Outperform rating from Leerink Partners indicates a positive outlook for ShockWave Medical. The price target of $263 suggests a significant upside potential from the current price. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100